LANGHORNE, Pa. (BUSINESS WIRE) Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that the company was added to the NASDAQ Biotech Index (Nasdaq: NBI), effective prior to market open on Monday, December 18, 2023.The NASDAQ Biotechnology Inde.
Savara (NASDAQ:SVRA) Sets New 12-Month High at $4.46 themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
Savara Inc. , a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will participate in a fireside chat at the Piper Sandler 35th.
Savara (NASDAQ:SVRA) Receives New Coverage from Analysts at Guggenheim kopsource.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from kopsource.com Daily Mail and Mail on Sunday newspapers.
Guggenheim began coverage on shares of Savara (NASDAQ:SVRA – Free Report) in a report issued on Tuesday morning, Marketbeat reports. The firm issued a buy rating and a $7.00 price objective on the stock. Separately, HC Wainwright boosted their price target on Savara from $3.00 to $6.00 and gave the company a buy rating in […]